Exagen (NASDAQ:XGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 9.68 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $12.51 million which missed the analyst consensus estimate of $13.56 million by 7.77 percent. This is a 6.78 percent decrease over sales of $13.42 million the same period last year.